Our research deals with the role of immune mechanisms in atherosclerosis. In particular, we investigate mechanisms of adaptive immunity, including immune activation, antigen specificity, cellular immune responses, proinflammatory effector mechanisms, and regulatory immunity. Recent work has identified (non-modified) LDL protein as a major antigen in disease and shown that mobilization of protective immunity towards this antigen significantly reduces disease in experimental models. We have identified key molecular and cellular pathways of atheroprotective immunity, with validation of experimental findings in human biobanks. Our goals are to elucidate the molecular immunopathology of atherosclerosis and help translating this knowledge into therapy.